Christine D. Baker, M.B.A

Targeting leukemia-supportive stromal signals in the bone marrow to achieve durable control in acute myeloid leukemia.

Christine D. Baker, MBA is a biotech CEO and company builder focused on advancing innovative oncology therapies. She is Co-Founder & CEO of Saatient Therapeutics, a Columbia University spin-out developing a first-in-class antibody approach for acute myeloid leukemia and related malignancies by targeting Serum Amyloid A1, a key bone marrow stromal driver of disease. Christine brings deep expertise in oncology strategy, product development, and early-stage company formation, with a track record of building high-performing teams and translating scientific insight into therapeutic programs. She is a Board Director and former non-executive director who works closely with academic and clinical leaders to advance new treatments for patients with high-unmet-need cancers.